Brief: Eliem Therapeutics Provides ETX-810 Program Update

Climb Bio

02/08/2022 12:38

Aug 2 (Reuters) - Eliem Therapeutics Inc  ELYM.O :
    * ELIEM THERAPEUTICS PROVIDES ETX-810 PROGRAM UPDATE
    * ELIEM THERAPEUTICS - IN PHASE 2A TRIAL IN LSRP, ETX-810
DID NOT
ACHIEVE STATISTICALLY SIGNIFICANT SEPARATION FROM PLACEBO ON
TRIAL'S PRIMARY ENDPOINT
    * ELIEM THERAPEUTICS - RESULT IS CONSISTENT WITH LACK OF
SEPARATION FROM PLACEBO OBSERVED IN PHASE 2A CLINICAL TRIAL IN
DPNP, AS REPORTED IN APRIL 2022
    * ELIEM THERAPEUTICS INC - ELECTED TO DISCONTINUE FURTHER
DEVELOPMENT OF ETX-810
    * ELIEM THERAPEUTICS INC - WITH DISCONTINUATION OF ETX-810,
ANTICIPATES THAT ITS CASH RUNWAY WILL EXTEND BEYOND MID-2024

Source text for Eikon:  ID:nGNXdHFb8 
Further company coverage:  ELYM.O 

 ((Reuters.Briefs@thomsonreuters.com;))